Generic Name and Formulations:
Mexiletine HCl 150mg, 200mg, 250mg; caps.
Various generic manufacturers
Indications for Mexiletine:
Documented life-threatening ventricular arrhythmias.
Take with food or antacid. Initially 200mg every 8hrs. Adjust dose if needed at not less than 2–3 day intervals in 50–100mg increments. Usual dose: 200–300mg every 8hrs; max 1.2g/day. If arrhythmia is controlled by ≤300mg every 8hrs, may try dividing same daily dose every 12hrs; max 450mg every 12hrs. See literature for information on rapid induction and changing from other antiarrhythmics.
Cardiogenic shock. 2nd- or 3rd- degree AV block unless paced.
Hepatic impairment. Severe heart failure. Sinus node dysfunction or intraventricular conduction defects. Hypotension. Epilepsy. Monitor ECG, blood and liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate other antiarrhythmics, theophylline. Monitor control if used with hepatic enzyme-inducing drugs. Avoid drugs or diets that alter urinary pH.
Class IB antiarrhythmic.
GI upset, dizziness, tremor, nervousness, ataxia, chest pain, blurred vision, exacerbated arrhythmias, hepatotoxicity.
Formerly known under the brand name Mexitil.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma